BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nouhaud E, Créhange G, Cueff A, Quivrin M, Rouffiac-Thouant M, Mineur L, Garcia R, Chamois J, Maingon P. Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy. BMC Res Notes 2013;6:492. [PMID: 24279802 DOI: 10.1186/1756-0500-6-492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Maingon P. Argumentaire clinique pour la radiothérapie guidée par imagerie par résonance magnétique. Cancer/Radiothérapie 2016;20:558-63. [DOI: 10.1016/j.canrad.2016.07.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Maingon P, Nouhaud É, Mornex F, Créhange G. Stereotactic body radiation therapy for liver tumours. Cancer/Radiothérapie 2014;18:313-9. [DOI: 10.1016/j.canrad.2014.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 McCulloch MM, Muenz DG, Schipper MJ, Velec M, Dawson LA, Brock KK. A simulation study to assess the potential impact of developing normal tissue complication probability models with accumulated dose. Adv Radiat Oncol 2018;3:662-72. [PMID: 30370368 DOI: 10.1016/j.adro.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56:561-567. [PMID: 25691453 DOI: 10.1093/jrr/rru130] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
5 Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 2019;18:e349-60. [PMID: 31351862 DOI: 10.1016/j.clcc.2019.06.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Doi H, Masai N, Uemoto K, Suzuki O, Shiomi H, Tatsumi D, Oh RJ. Validation of the liver mean dose in terms of the biological effective dose for the prevention of radiation-induced liver damage. Rep Pract Oncol Radiother 2017;22:303-9. [PMID: 28507460 DOI: 10.1016/j.rpor.2017.02.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
7 Dang YZ, Huang SG, Lu WL, Wu FW, Wang QY. Curative effect of stereotactic body radiotherapy on hepatic hilar carcinoma. Mol Clin Oncol 2014;2:1135-8. [PMID: 25279211 DOI: 10.3892/mco.2014.395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]